Literature DB >> 30680770

Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma.

Surbhi Sidana1, Dragan Jevremovic2, Rhett P Ketterling2, Nidhi Tandon1, Patricia T Greipp2, Linda B Baughn2, Angela Dispenzieri1, Morie A Gertz1, Sundararajan Vincent Rajkumar1, Shaji K Kumar1.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 30680770      PMCID： PMC8019381          DOI： 10.1002/ajh.25420

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  16 in total

1.  Hypodiploidy is a major prognostic factor in multiple myeloma.

Authors:  N V Smadja; C Bastard; C Brigaudeau; D Leroux; C Fruchart
Journal:  Blood       Date:  2001-10-01       Impact factor: 22.113

2.  Plasma cell labeling index.

Authors:  Philip R Greipp; Shaji Kumar
Journal:  Methods Mol Med       Date:  2005

3.  Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience.

Authors:  Benjamin Hebraud; Florence Magrangeas; Alice Cleynen; Valerie Lauwers-Cances; Marie-Lorraine Chretien; Cyrille Hulin; Xavier Leleu; Edwige Yon; Gerald Marit; Lionel Karlin; Murielle Roussel; Anne-Marie Stoppa; Karim Belhadj; Laurent Voillat; Laurent Garderet; Margaret Macro; Denis Caillot; Mohamad Mohty; Thierry Facon; Philippe Moreau; Michel Attal; Nikhil Munshi; Jill Corre; Stephane Minvielle; Herve Avet-Loiseau
Journal:  Blood       Date:  2015-01-30       Impact factor: 22.113

4.  Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics.

Authors:  Shaji Kumar; Rafael Fonseca; Rhett P Ketterling; Angela Dispenzieri; Martha Q Lacy; Morie A Gertz; Suzanne R Hayman; Francis K Buadi; David Dingli; Ryan A Knudson; Alexandra Greenberg; Stephen J Russell; Steven R Zeldenrust; John A Lust; Robert A Kyle; Leif Bergsagel; S Vincent Rajkumar
Journal:  Blood       Date:  2012-01-10       Impact factor: 22.113

5.  Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.

Authors:  S Rajkumar; R Fonseca; M Lacy; T Witzig; J Lust; P Greipp; T Therneau; R Kyle; M Litzow; M Gertz
Journal:  Bone Marrow Transplant       Date:  1999-09       Impact factor: 5.483

6.  Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie.

Authors:  Prashant Kapoor; Rafael Fonseca; S Vincent Rajkumar; Shirshendu Sinha; Morie A Gertz; A Keith Stewart; P Leif Bergsagel; Martha Q Lacy; David D Dingli; Rhett P Ketterling; Francis Buadi; Robert A Kyle; Thomas E Witzig; Philip R Greipp; Angela Dispenzieri; Shaji Kumar
Journal:  Mayo Clin Proc       Date:  2010-06       Impact factor: 7.616

7.  Near-tetraploidy clone can evolve from a hyperdiploidy clone and cause resistance to lenalidomide and bortezomib in a multiple myeloma patient.

Authors:  Ji Yuan; Radhika Shah; Anita Kulharya; Celalettin Ustun
Journal:  Leuk Res       Date:  2010-07       Impact factor: 3.156

8.  A pooled analysis of karyotypic patterns, breakpoints and imbalances in 783 cytogenetically abnormal multiple myelomas reveals frequently involved chromosome segments as well as significant age- and sex-related differences.

Authors:  Thérèse Nilsson; Mattias Höglund; Stig Lenhoff; Lars Rylander; Ingemar Turesson; Jan Westin; Felix Mitelman; Bertil Johansson
Journal:  Br J Haematol       Date:  2003-03       Impact factor: 6.998

9.  Clinical and biologic implications of recurrent genomic aberrations in myeloma.

Authors:  Rafael Fonseca; Emily Blood; Montserrat Rue; David Harrington; Martin M Oken; Robert A Kyle; Gordon W Dewald; Brian Van Ness; Scott A Van Wier; Kimberly J Henderson; Richard J Bailey; Philip R Greipp
Journal:  Blood       Date:  2003-02-06       Impact factor: 22.113

10.  The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma.

Authors:  Rafael Fonseca; Carina S Debes-Marun; Elisa B Picken; Gordon W Dewald; Sandra C Bryant; Jerry M Winkler; Emily Blood; Martin M Oken; Rafael Santana-Dávila; Natalia González-Paz; Robert A Kyle; Morie A Gertz; Angela Dispenzieri; Martha Q Lacy; Philip R Greipp
Journal:  Blood       Date:  2003-06-12       Impact factor: 22.113
View more
  4 in total

Review 1.  High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions.

Authors:  Patrick Hagen; Jiwang Zhang; Kevin Barton
Journal:  Blood Cancer J       Date:  2022-05-30       Impact factor: 9.812

2.  Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma.

Authors:  James Smadbeck; Jess F Peterson; Kathryn E Pearce; Beth A Pitel; Andrea Lebron Figueroa; Michael Timm; Dragan Jevremovic; Min Shi; A Keith Stewart; Esteban Braggio; Daniel L Riggs; P Leif Bergsagel; George Vasmatzis; Hutton M Kearney; Nicole L Hoppman; Rhett P Ketterling; Shaji Kumar; S Vincent Rajkumar; Patricia T Greipp; Linda B Baughn
Journal:  Blood Cancer J       Date:  2019-12-16       Impact factor: 11.037

Review 3.  Genetic Predictors of Mortality in Patients with Multiple Myeloma.

Authors:  Hamza Hassan; Raphael Szalat
Journal:  Appl Clin Genet       Date:  2021-04-29

4.  Context-dependent effects of whole-genome duplication during mammary tumor recurrence.

Authors:  Rachel Newcomb; Emily Dean; Brock J McKinney; James V Alvarez
Journal:  Sci Rep       Date:  2021-07-22       Impact factor: 4.996
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.